A Study of Retreatment With Rituximab in Patients With Rheumatoid Arthritis Receiving Background Methotrexate
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase III, randomized, double-blind, placebo-controlled, multicenter study
evaluating the efficacy of retreatment with rituximab in subjects with active rheumatoid
arthritis (RA) who are receiving Methotrexate (MTX).